The impact of emicizumab on the clinical validation of new therapies for haemophilia A

Hermans, Cédric;Lambert, Catherine;Lobet, Sébastien;Krumb, Evelien;Van Damme, An
(2025) Haemophilia (Print) — Vol. 31, n° 2, p. 331-333 (2025)

Files

Haemophilia-2024-Hermans-TheimpactofemicizumabontheclinicalvalidationofnewtherapiesforhaemophiliaA.pdf
  • Restricted Access
  • Adobe PDF
  • 196.13 KB
Request a copy

Details

Authors
Abstract
(en) Numerous therapeutic innovations for haemophilia have emerged over the last decades.1, 2 They were initially motivated by the need to abolish the risk of infection and contamination associated with the first generations of plasma-derived products. More recently their development was driven by the intention to reduce the burden of prophylaxis by enhancing their pharmacokinetic properties or facilitating their administration with subcutaneous procoagulant agents, all of them providing improved haemostatic control. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Hermans, C., Lambert, C., Lobet, S., Krumb, E., & Van Damme, A. (2025). The impact of emicizumab on the clinical validation of new therapies for haemophilia A. Haemophilia (Print), 31(2), 331-333. https://doi.org/10.1111/hae.15112 (Original work published 2025)